THE IPO window for life science companies has finally cracked open, and unlisted companies are increasingly looking towards the public capital markets as an option to raise the cash for their next stage in product development. But floating a biotech is a tricky business. McCullough Robertson partner Reece Walker talks through the basics of a biotech IPO.

Click here to read the rest of today's news stories.